Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 18, 2011, Pages 7613-7618

  Sampah, Maame Efua S ^a   Shen, Lin ^a   Jilek, Benjamin L ^a   Siliciano, Robert F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Evolution; Highly active antiretroviral therapy; HIV AIDS; Pharmacology; Virology

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DARUNAVIR; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TIPRANAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; DOSE RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; PRIORITY JOURNAL; T LYMPHOBLAST; VIRUS MUTATION; VIRUS REPLICATION;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV FUSION INHIBITORS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; MUTATION; REGRESSION ANALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79956291343     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018360108     Document Type: Article

References (59)

1. Larder BA, Darby G, Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734. (Pubitemid 19106971)
2. Coffin JM (1995) HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
3. Wei X, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
4. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350:1023-1035. (Pubitemid 38269279)
5. Hirsch MS, et al.; International AIDS Society-USA (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med 16:266-285.
6. Shafer RW, Schapiro JM (2008) HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 10:67-84.
7. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR (2009) Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 23:1035-1046.
8. Preston BD, Poiesz BJ, Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171. (Pubitemid 19007042)
9. Roberts JD, Bebenek K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173. (Pubitemid 19007043)
10. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087-5094.
11. Tisdale M, Kemp SD, Parry NR, Larder BA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 90: 5653-5656. (Pubitemid 23176219)
12. Richman DD (1990) Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. Am J Med 88(5B) (Suppl):8S-10S.
13. Boyer PL, Currens MJ, McMahon JB, Boyd MR, Hughes SH (1993) Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 67:2412-2420. (Pubitemid 23088424)
14. Race E, Dam E, Obry V, Paulous S, Clavel F (1999) Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 13:2061-2068. (Pubitemid 29509582)
15. Miller V, Larder BA (2001) Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 6(Suppl 3):25-44. (Pubitemid 32938761)
16. Back NK, et al. (1996) Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15:4040-4049. (Pubitemid 26289813)
17. Goudsmit J, de Ronde A, de Rooij E, de Boer R (1997) Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 71:4479-4484. (Pubitemid 27204138)
18. Croteau G, et al. (1997) Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 71:1089-1096. (Pubitemid 27030280)
19. Quiñones-Mateu MEAE (2001) HIV-1 fitness: Implications for drug resistance, disease progression, and global epidemic evolution. HIV Sequence Compendium 2001, eds Kuiken C, et al. (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM) pp 134-170.
20. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
21. Ding J, et al. (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 2:407-415.
22. Das K, et al. (1996) Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 264:1085-1100.
23. Mahalingam B, Louis JM, Hung J, Harrison RW, Weber IT (2001) Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43:455-464. (Pubitemid 32476440)
24. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA (1998) Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908-15917. (Pubitemid 28524762)
25. Meyer PR, Matsuura SE, So AG, Scott WA (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 95:13471-13476. (Pubitemid 28522996)
26. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA (1999) A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 4:35-43. (Pubitemid 29386129)
27. Japour AJ, et al. (1993) Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother 37:1095-1101. (Pubitemid 23141326)
28. Hertogs K, et al. (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42:269-276. (Pubitemid 28114430)
29. Petropoulos CJ, et al. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44:920-928. (Pubitemid 30165271)
30. Qari SH, et al. (2002) Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol 40:31-35. (Pubitemid 34027597)
31. Hill AV (1910) The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 40:iv-vii.
32. Chou TC (1976) Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59:253-276.
33. Shen L, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14:762-766. (Pubitemid 351951518)
34. Holford NH, Sheiner LB (1981) Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453. (Pubitemid 12213270)
35. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
36. Rhee SY, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31:298-303.
37. Shafer RW (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194(Suppl 1):S51-S58.
38. Johnson VA, et al. (2009) Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 17:138-145.
39. Ferguson NM, Fraser C, Anderson RM (2001) Viral dynamics and anti-viral pharmacodynamics: Rethinking in vitro measures of drug potency. Trends Pharmacol Sci 22:97-100. (Pubitemid 32146488)
40. Wainberg MA, et al. (1999) In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 4:87-94.
41. Naeger LK, Margot NA, Miller MD (2001) Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: Analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 6:115-126. (Pubitemid 32652096)
42. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ (2003) Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 188:992-1000. (Pubitemid 37268249)
43. Wolf K, et al. (2003) Tenofovir resistance and resensitization. Antimicrob Agents Chemother 47:3478-3484. (Pubitemid 37345707)
44. Cong ME, Heneine W, García-Lerma JG (2007) The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 81:3037-3041. (Pubitemid 46447070)
45. Quiñones-Mateu ME, Arts EJ (2002) Fitness of drug resistant HIV-1: Methodology and clinical implications. Drug Resist Updat 5:224-233. (Pubitemid 36132804)
46. Mammano F, Trouplin V, Zennou V, Clavel F (2000) Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J Virol 74:8524-8531. (Pubitemid 30666703)
47. Watkins T, Resch W, Irlbeck D, Swanstrom R (2003) Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 47:759-769. (Pubitemid 36158112)
48. Molla A, et al. (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2:760-766. (Pubitemid 26225091)
49. Bangsberg DR, Kroetz DL, Deeks SG (2007) Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 4:65-72. (Pubitemid 46806622)
50. Gallant JE, et al.; ESS30009 Study (2005) Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 192:1921-1930.
51. Khanlou H, Yeh V, Guyer B, Farthing C (2005) Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 19:135-140. (Pubitemid 40478291)
52. Underwood MR, et al. (2009) Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. J Infect Dis 199:84-88.
53. Dicker IB, et al. (2008) Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem 283:23599-23609.
54. Ala PJ, et al. (1997) Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 36:1573-1580. (Pubitemid 27086253)
55. Rhee SY, et al. (2010) HIV-1 protease mutations and protease inhibitor crossresistance. Antimicrob Agents Chemother 54:4253-4261.
56. MacArthur RD (2010) Instantaneous inhibitory potential and inhibitory quotient show a modest association with virologic outcome: Is either a useful surrogate for clinical drug efficacy? Clin Infect Dis 51:99-100.
57. Henrich TJ, Ribaudo HJ, Kuritzkes DR (2010) Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy. Clin Infect Dis 51:93-98.
58. Shen L, Siliciano RF (2010) Achieving a quantitative understanding of antiretroviral drug efficacy. Clin Infect Dis 51:1105-1106, author reply 1106-1107.
59. Zhang H, et al. (2004) Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 78:1718-1729. (Pubitemid 38176704)